home / stock / ptgx / ptgx quote
Last: | $25.61 |
---|---|
Change Percent: | 0.44% |
Open: | $25.11 |
Close: | $25.61 |
High: | $25.625 |
Low: | $24.79 |
Volume: | 452,280 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$25.61 | $25.11 | $25.61 | $25.625 | $24.79 | 452,280 | 04-19-2024 |
$25.22 | $25.34 | $25.22 | $25.755 | $25.17 | 434,151 | 04-18-2024 |
$25.57 | $26.39 | $25.57 | $26.39 | $25.35 | 517,565 | 04-17-2024 |
$26.11 | $26.3 | $26.11 | $26.4 | $25.93 | 524,120 | 04-16-2024 |
$26.58 | $27.18 | $26.58 | $27.35 | $26.32 | 441,002 | 04-15-2024 |
$27.04 | $27.52 | $27.04 | $27.565 | $26.655 | 637,955 | 04-12-2024 |
$27.66 | $28.2 | $27.66 | $28.4 | $27.365 | 542,987 | 04-11-2024 |
$27.88 | $28.22 | $27.88 | $28.54 | $27.74 | 704,287 | 04-10-2024 |
$29.13 | $28.15 | $29.13 | $29.21 | $27.9375 | 885,934 | 04-09-2024 |
$28.09 | $28.06 | $28.09 | $28.11 | $27.43 | 313,517 | 04-08-2024 |
$28 | $27.45 | $28 | $28.61 | $26.92 | 395,557 | 04-05-2024 |
$27.65 | $28.42 | $27.65 | $29 | $27.55 | 777,312 | 04-04-2024 |
$28.07 | $27.71 | $28.07 | $28.4 | $27.71 | 655,516 | 04-03-2024 |
$27.99 | $27.74 | $27.99 | $28.11 | $27.59 | 731,802 | 04-02-2024 |
$28.28 | $28.77 | $28.28 | $28.895 | $27.64 | 842,199 | 04-01-2024 |
$28.93 | $28.42 | $28.93 | $29.27 | $28.13 | 653,366 | 03-29-2024 |
$28.93 | $28.42 | $28.93 | $29.27 | $28.13 | 653,366 | 03-28-2024 |
$28.48 | $28.17 | $28.48 | $28.62 | $27.94 | 359,436 | 03-27-2024 |
$28 | $28.42 | $28 | $28.42 | $27.585 | 307,470 | 03-26-2024 |
$27.89 | $28.11 | $27.89 | $28.44 | $27.625 | 247,394 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected t...
2024-04-04 04:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced it has randomized 241 pat...